SCHEMBL2089059

SCHEMBL2089059

CC=C(OC)c1cc(OC)cc(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
PDE4A P27815 2/20 0.46
PDE4B Q07343 2/20 0.46
PDE4C Q08493 2/20 0.46
PDE4D Q08499 2/20 0.46
CYP1A1 P04798 2/20 0.44
CYP1B1 Q16678 2/20 0.44
ALPL P05186 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
KMT2A Q03164 3/20 0.43
GAA P10253 2/20 0.43
CYP1A2 P05177 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2096154 0.79 CES2 (0.58) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL2093782 0.78 NPC1 (0.38) ALDH1A1SMN1; SMN2KMT2AGAANPC1
SCHEMBL2091071 0.77 CA1 (0.54) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL2096862 0.74 ALDH1A1 (0.52) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL20331772 0.74 ALDH1A1 (0.46) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL2093047 0.73 MEN1 (0.40) ALDH1A1SMN1; SMN2KMT2ANPC1RAB9A
1,3,5-Trimethoxybenzene SCHEMBL28493 0.71 ALDH1A1 (1.00) ALDH1A1CYP1A1CYP1B1CYP1A2CYP3A4
SCHEMBL40552 0.70 ALDH1A1 (0.61) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL25508540 0.70 CES2 (0.64) ALDH1A1CYP1A1CYP1B1SMN1; SMN2KMT2A
Methyl 3,5-Dimethoxybenzoate SCHEMBL204865 0.70 CA1 (0.61) ALDH1A1SMN1; SMN2KMT2AGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ALDH1A1 412/4885PDE4A 3611/4885PDE4B 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.